in its filing to the exchanges on Friday informed that the company has launched Clobazam Oral Suspension 2.5mg/mL after having received approval from the United States Food and Drug Administration (USFDA) earlier.
"Lupin's Clobazam Oral Suspension, 2.5mg/mL is the generic version of Lundbeck Pharmaceuticals LLC's Onfi Oral Suspension, 2.5mg/ml," the company said in a press note to the exchanges on Friday
It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
As per data released by IQVIA MAT December 2018, Clobazam Oral Suspension, 2.5mg/mL had annual sales of $253mn in the US.
Lupin Ltd's share price is currently at Rs773, down by Rs37.85 or 4.67%, from its previous close of Rs810.85 on the BSE.
The scrip opened at Rs807 and has touched a high and low of Rs808.75 and Rs769.85, respectively. So far, 26,55,480 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs36,687.05cr.